Piper Sandler raised the firm’s price target on Arcellx (ACLX) to $115 from $91 and keeps an Overweight rating on the shares following Q3 ...

Based on the latest available data, ACLX has gained about 78.7% so far this year. Meanwhile, the Medical sector has returned an average of 4% on a year-to-date basis. This means that Arcellx, Inc. is ...

The median progression-free survival and overall survival had not yet been reached. Additionally, Arcellx announced yesterday that updated data from the Phase 1 study will be presented at ASH. In the ...

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on ACLX stock, giving a Buy rating on November 6. Tyler Van Buren has ...

Arcellx (NASDAQ:ACLX – Get Free Report) had its price target increased by Morgan Stanley from $81.00 to $106.00 in a research ...

Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.81 per share a year ago. These figures are ...

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today ...

Arcellx, Inc. (ACLX) shares rallied 6.7% in the last trading session to close at $92.98. This move can be attributable to ...

Santa Monica, California Thursday, November 7, 2024, 10:00 Hrs [IST] ...

On Tuesday, Arcellx Inc (ACLX) stock saw a modest uptick, ending the day at $87.12 which represents a slight increase of $0.68 or 0.79% from the prior close of $86.44. The stock opened at $80.22 and ...

Shares of AstraZeneca dropped more than 7% yesterday after the Chinese publication Yicai Global reported that dozens of ...